Amorphous solid dispersion

Developing a non-crystalline API is an approach that can improve the apparent solubility and oral bioavailability of a poorly water-soluble API. In order to stabilise an amorphous form, the API is combined in a single-phase amorphous mixture, amorphous dispersion, with a polymer to inhibit crystallisation over the shelf life of the drug product.

• Increased solubility and bioavailability
• Stabilised amorphous forms
• Controlled particle size distribution